including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic ...

“The suzetrigine Phase 2 results clearly show reduced pain intensity from baseline in the active ... autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

EDO51, an investigational therapy for Duchenne muscular dystrophy (DMD), and is still ongoing in the United Kingdom.

Wellington Management Group LLP decreased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) by 81.6% in the ...

The "Myotonic Dystrophy - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth understanding of Myotonic Dystrophy, historical and ...

A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days ...

Season 1 excelled in visual aesthetics and storytelling, while Season 2 was more creative but faced criticisms for its rushed pace. Both seasons of Arcane were successful and well-received.

Scroll down to read more. Pushpa 2: The Rule the sequel to Pushpa: The Rise continues to set new benchmarks in the Indian cinema. With its record-breaking milestones, Pushpa 2 has crossed the ...

PepGen (PEPG) announced that the FDA has placed a clinical hold on the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in Duchenne muscular ... of what happened to PepGen when they initiated U.S. sites in ...

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $25.61, but opened at $26.42. Dyne Therapeutics shares last ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...